Lumida
/LXRX
⌘K
Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

LXRX
$2.00USD-0.99%-0.02 today

MARKET CAP

889.9M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
Sell NowMedium

The stock has lost intermediate EMA control with 9/20 EMAs crossing below the 50-day SMA and price closing decisively underneath, indicating structural repair to the downside. Price trading beneath converged EMAs with flat to downward tilt and neutral momentum signals confirms a bearish medium-term bias. Short-term timing is unfavorable for new longs, and the tradable side is bearish. Engagement should occur on rallies into the $2.30–$2.35 resistance zone at the EMA cluster, using rejection setups.

  • JACC: Heart Failure study shows sotagliflozin efficacy at low systolic BP
  • Received $10M milestone payment from Novo Nordisk for LX9851
  • Negative earnings yield (-0.11) and weak profitability raise concerns
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2020FY 2023FY 2024FY 2025TREND
Sales, Adj.$321.6M$23.4M$1.1M$31.0M$49.6M
YoY %+411.6%-92.7%+2692.9%+60.1%
P / Sales1.5x16.2x316.8x7.6x8.4x
EV / Sales2.3x12.8x419.3x10.4x9.3x
Gross Profit, Adj.$318.3M$21.5M$1.0M$30.4M$49.4M
YoY %+427.4%-93.2%+2864.4%+62.5%
Margin %99.0%91.8%92.3%98.0%99.4%
EV / Gross Profit2.4x14.0x454.1x10.6x9.3x
EBITDA, Adj.$173.2M$-176.4M$-171.3M$-196.7M$-48.4M
YoY %+273.3%-201.8%-65.9%-14.8%+75.4%
Margin %53.9%-752.7%-15431.5%-634.4%-97.6%
EV / EBITDA4.3x-1.7x-2.7x-1.6x-9.5x
EBIT$140.9M$-180.9M$-171.8M$-197.2M$-49.1M
YoY %+236.0%-228.4%-65.7%-14.8%+75.1%
Margin %43.8%-772.0%-15481.4%-636.1%-98.8%
EV / EBIT5.3x-1.7x-2.7x-1.6x-9.4x
Net Income$130.1M$-58.6M$-177.1M$-200.4M$-50.3M
YoY %+208.0%-145.0%-73.7%-13.1%+74.9%
Net Margin40.5%-249.9%-15956.7%-646.4%-101.4%
EPS (GAAP)$1.16-$0.53-$0.80-$0.63-$0.14
YoY %+201.8%-145.7%-29.0%+21.3%+77.8%